Thursday, 10 May 2012

Macular Degeneration-Drugmaker Novartis-Lucentis

Novartis eye drug efficient over longer term: studies

ZURICH (Reuters) - Swiss drugmaker Novartis said on Thursday data from key studies showed treatment with its Lucentis drug could help certain sight-impaired patients see better over an extended period and that individualized treatment improved results. Lucentis, with annualized sales for Novartis of $2 billion, is licensed for wet age-related macular degeneration (AMD). ... read more..

No comments:

Post a Comment